390 related articles for article (PubMed ID: 33441389)
21. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
22. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
23. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract][Full Text] [Related]
24. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response.
Ross ME; Caligiuri MA
Blood; 1997 Feb; 89(3):910-8. PubMed ID: 9028322
[TBL] [Abstract][Full Text] [Related]
26. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.
Küçükköse E; Heesters BA; Villaudy J; Verheem A; Cercel M; van Hal S; Boj SF; Borel Rinkes IHM; Punt CJA; Roodhart JML; Laoukili J; Koopman M; Spits H; Kranenburg O
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543378
[TBL] [Abstract][Full Text] [Related]
27. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
Arina A; Murillo O; Hervás-Stubbs S; Azpilikueta A; Dubrot J; Tirapu I; Huarte E; Alfaro C; Pérez-Gracia JL; González-Aseguinolaza G; Sarobe P; Lasarte JJ; Jamieson A; Prieto J; Raulet DH; Melero I
Int J Cancer; 2007 Sep; 121(6):1282-95. PubMed ID: 17520674
[TBL] [Abstract][Full Text] [Related]
28. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
29. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
[TBL] [Abstract][Full Text] [Related]
30. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
32. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
33. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
[TBL] [Abstract][Full Text] [Related]
35. Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response.
Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Fuchinoue S; Goldenberg DM; Kubota K
Am J Surg; 2012 Oct; 204(4):527-34. PubMed ID: 22658578
[TBL] [Abstract][Full Text] [Related]
36. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
37. Soypeptide lunasin in cytokine immunotherapy for lymphoma.
Chang HC; Lewis D; Tung CY; Han L; Henriquez SM; Voiles L; Lupov IP; Pelloso D; Sinn AL; Pollok KE; de Lumen BO; Li F; Blum JS; Srivastava S; Robertson MJ
Cancer Immunol Immunother; 2014 Mar; 63(3):283-95. PubMed ID: 24363024
[TBL] [Abstract][Full Text] [Related]
38. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
Jaime-Ramirez AC; Mundy-Bosse BL; Kondadasula S; Jones NB; Roda JM; Mani A; Parihar R; Karpa V; Papenfuss TL; LaPerle KM; Biller E; Lehman A; Chaudhury AR; Jarjoura D; Burry RW; Carson WE
J Immunol; 2011 Mar; 186(6):3401-9. PubMed ID: 21321106
[TBL] [Abstract][Full Text] [Related]
39. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
40. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
